Abbott India Q1 FY27 Results: PAT up 17%, revenue 4%

Key takeaway from the June 2026 quarter

Abbott India reported a steady rise in revenue and a faster increase in profit for the quarter ended June 30, 2026 (Q1 FY27). The company’s unaudited results were approved by its Board of Directors on August 12, 2026, and were stated to be prepared under Ind AS 34 and Regulation 33 of SEBI Listing Regulations. On the day of the result, reports cited the stock trading around ₹27,560, while another market snapshot listed CMP at ₹27,835.

At the headline level, revenue from operations for the quarter was ₹1,813.68 crore, while profit after tax (PAT) was ₹428.52 crore. The company also disclosed total income of ₹1,889.05 crore, which includes other income of ₹75.37 crore.

Standalone highlights: income, operating profit, and PAT

For Q1 FY27, Abbott India’s standalone total income was ₹1,889.05 crore. Revenue from operations was ₹1,813.68 crore, while other income contributed ₹75.37 crore. Profit before tax (PBT) stood at ₹572.21 crore, and tax expense was ₹143.69 crore.

PAT for the quarter came in at ₹428.52 crore. Total comprehensive income (net of tax) was reported at ₹428.56 crore, with other comprehensive income of ₹0.04 crore. Earnings per equity share (basic and diluted, not annualised) were ₹201.66.

Year-on-year comparison: growth concentrated in profitability

The company’s performance in Q1 FY27 reflected modest top-line growth but stronger profit expansion. A separate comparison table in the provided data set showed revenue from operations at ₹1,813 crore in Q1 FY27 versus ₹1,738 crore in Q1 FY26, implying 4.33% year-on-year growth. It also showed PAT of ₹428 crore versus ₹365 crore, up 17.13% year-on-year.

Operating income (also described as operating profit in the quarterly data table) was ₹502.75 crore for Jun 2026, compared with ₹372.64 crore for Jun 2024 in the same table, indicating a 17.99% year-on-year increase as presented there. The operating margin was listed at 27.72% in the highlights, with a year-on-year change shown alongside it.

Sequential comparison: Q1 FY27 versus Q4 FY26 (as provided)

The quarterly table also included the immediately preceding quarter (Mar 2026 / Q4 FY26). Total revenue increased to ₹1,813.68 crore from ₹1,709.51 crore, a QoQ rise of 6.09%. Net income rose to ₹428.52 crore from ₹394.93 crore, a QoQ increase of 8.51%.

Operating income was ₹502.75 crore versus ₹461.78 crore in the previous quarter, a QoQ rise of 8.87%. Diluted normalised EPS was listed at ₹201.66 compared with ₹179.93 in the previous quarter.

Cost structure and expense lines disclosed for the quarter

Abbott India disclosed total expenses of ₹1,316.84 crore for Q1 FY27. The expense disclosure included cost of materials consumed of ₹150.63 crore and purchases of stock-in-trade of ₹812.06 crore. Changes in inventories were shown as (₹31.10) crore.

Employee benefits expense was ₹175.24 crore. Finance costs were ₹5.91 crore, while depreciation and amortisation stood at ₹19.75 crore. Other expenses were reported at ₹184.35 crore. The same quarterly table also listed selling, general and administrative expenses total at ₹175.24 crore for Jun 2026.

Consolidated snapshot: EBITDA and margin expansion (as reported)

Alongside standalone disclosures, the provided material also cited consolidated performance metrics for Q1 FY27. Consolidated revenue was stated at ₹1,813.6 crore, up 4.3% year-on-year from ₹1,738.4 crore. Consolidated net profit was reported at ₹429 crore versus ₹366 crore, up 17.12%.

Consolidated EBITDA was reported at ₹522.4 crore versus ₹445.5 crore a year ago, an increase of 17.3%. The EBITDA margin was stated at 28.81% in Q1 FY27 versus 25.63% in Q1 FY26.

Key numbers at a glance

Governance and audit notes included in the disclosure

The company stated that the results were reviewed by the Audit Committee and approved by the Board. The statutory auditors, Walker Chandiok & Co LLP, issued an unqualified Limited Review Report, as mentioned in the provided text.

Abbott India had also intimated the stock exchange that its board meeting was scheduled on August 12, 2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026.

Full-year FY26 reference points (audited)

The dataset also included audited figures for the year ended March 31, 2026. Revenue from operations for FY26 was ₹6,929.05 crore and other income was ₹288.14 crore, taking total income to ₹7,217.19 crore. Total expenses for the year were ₹5,137.92 crore.

Profit for the year was reported at ₹1,552.02 crore, and EPS for the year was ₹730.36. The note added that the figures for the quarter ended March 31, 2026 were balancing figures between audited annual results and published year-to-date figures.

What investors typically track from this update

For Q1 FY27, the clearest message in the numbers is the gap between revenue growth (about 4% year-on-year in the summaries provided) and profit growth (about 17%). The company’s quarterly disclosures also show higher operating income and higher net income compared with the previous quarter (Mar 2026) in the provided table.

Investors will also track the movement in profitability metrics across different presentations. The standalone highlights included an operating margin of 27.72%, while consolidated reporting cited an EBITDA margin of 28.81% for Q1 FY27. Any further clarity on reconciliation between standalone operating profit and consolidated EBITDA is typically derived from detailed financial statements and notes.

Conclusion

Abbott India’s Q1 FY27 results, approved on August 12, 2026, showed revenue from operations of ₹1,813.68 crore and PAT of ₹428.52 crore for the quarter ended June 30, 2026. The company also reported total income of ₹1,889.05 crore and profit before tax of ₹572.21 crore, backed by detailed expense disclosures.

The next set of updates for investors will come through subsequent quarterly filings and board approvals, with continued focus on margins, operating profitability, and the pace of revenue growth versus profit growth.